Trial Profile

Phase II clinical study of Soluble TNF inhibitor

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegipanermin (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; Hypoxia
Focus Therapeutic Use

Most Recent Events

01 Sep 2020 According to an Inmune Bio media release, the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to initiate this study.
14 May 2020 According to an Inmune Bio media release, the company expects to submit IND application in May 2020 and expects to enroll first patient as soon as possible.
24 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com